LUNCH WORKSHOP 2
Thursday, 3 October 2019 | 12.00-13.30 | Hotel Das Alpenhaus
The cannabis plant has been used for medical and recreational purposes across the world for centuries. Today, cannabis and cannabinoid products have found their way into modern medicine and are positioning themselves as alternate avenues of treatment for pain management, drug abuse disorders and a range of other indications like epilepsy, neurodegenerative and psychotic disorders.
With increased use of medical cannabis and cannabinoids comes a need for comprehensive risk-benefit discussions that take into account the state of clinical evidence on both the potential therapeutic value and side effects for patients, as well as the regulatory challenges and implications. As EU Member States implement medical and recreational cannabis policies that often diverge signifcantly from one country to another, and as more people turn to medical cannabis as a treatment option, this session will explore approaches to legislation and regulation across Europe and beyond, and ask: will cannabis products be a transformative force for quality of life in the future, or do the risks and obstacles outweigh the rewards?
LIESBETH VANDAM, Head of Sector ‘Support to Policy’, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
PHILIP MCGUIRE, Head of Department of Psychosis Studies, King’s College London
IAN HAMILTON, Senior Lecturer in Addiction and Mental Health, University of York
PAOLA KRUGER, EUPATI Fellow, Italy
NATASHA AZZOPARDI-MUSCAT, Consultant, Public Health Medicine, Directorate for Health Information & Research, Malta, & President, European Public Health Association (EUPHA)